

CITATION REPORT

List of articles citing

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease

DOI: 10.1097/ftd.0000000000000494
Therapeutic Drug Monitoring, 2018, 40, 202-211.

Source: <https://exaly.com/paper-pdf/69443003/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
19	Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 169-187	6.2	20
18	Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 885-891	3.8	5
17	Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. <i>BioDrugs</i> , 2019 , 33, 453-468	7.9	7
16	Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1248-1256	1.5	26
15	Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. <i>Antibodies</i> , 2019 , 8,	7	22
14	Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 37-49	6.2	13
13	Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 289-294	3.2	7
12	Immunogenicity of TNF-Inhibitors. <i>Frontiers in Immunology</i> , 2020 , 11, 312	8.4	39
11	Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 857-874	6.2	16
10	Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3162-3176	3.8	1
9	Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease. <i>Pharmaceutics</i> , 2021 , 13,	6.4	1
8	Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease. <i>European Journal of Pharmaceutical Sciences</i> , 2020 , 150, 105369	5.1	3
7	Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 795272	5.6	0
6	Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies.. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022 ,	5.5	1
5	Adalimumab with methotrexate versus adalimumab monotherapy in psoriasis: First-year results of a single-blind randomized controlled trial.. <i>Journal of Investigative Dermatology</i> , 2022 ,	4.3	0
4	Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis.. <i>Scientific Reports</i> , 2022 , 12, 4670	4.9	0
3	Population Pharmacokinetic Evaluation with External Validation of Tacrolimus in Chinese Primary Nephrotic Syndrome Patients. <i>Pharmaceutical Research</i> ,	4.5	0

- 2 Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis. **2023**, 62, 623-634 ○
- 1 Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial. ○